Pasar al contenido principal

MECANISMOS MOLECULARES DE LOS SINTOMAS NO MOTORES EN LA ENFERMEDAD DE PARKINSON: PAPEL DE LA ACUMULACION DE LA A-SINUCLEINA, GBA1 Y EL PETABOLISMO LIPIDICO

PID2019-111693RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 15
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Role of Cholesterol in α-Synuclein and Lewy Body Pathology in GBA1 Parkinson's Disease

  • García-Sanz, Patricia
  • Aerts, Johannes
  • Moratalla, Rosario
Parkinson's disease (PD) is a progressive neurodegenerative disease where dopaminergic neurons in the substantia nigra are lost, resulting in a decrease in striatal dopamine and, consequently, motor control. Dopaminergic degeneration is associated with the appearance of Lewy bodies, which contain membrane structures and proteins, including α-synuclein (α-Syn), in surviving neurons. PD displays a multifactorial pathology and develops from interactions between multiple elements, such as age, environmental conditions, and genetics. Mutations in the GBA1 gene represent one of the major genetic risk factors for PD. This gene encodes an essential lysosomal enzyme called β-glucocerebrosidase (GCase), which is responsible for degrading the glycolipid glucocerebroside into glucose and ceramide. GCase can generate glucosylated cholesterol via transglucosylation and can also degrade the sterol glucoside. Although the molecular mechanisms that predispose an individual to neurodegeneration remain unknown, the role of cholesterol in PD pathology deserves consideration. Disturbed cellular cholesterol metabolism, as reflected by accumulation of lysosomal cholesterol in GBA1-associated PD cellular models, could contribute to changes in lipid rafts, which are necessary for synaptic localization and vesicle cycling and modulation of synaptic integrity. α-Syn has been implicated in the regulation of neuronal cholesterol, and cholesterol facilitates interactions between α-Syn oligomers. In this review, we integrate the results of previous studies and describe the cholesterol landscape in cellular homeostasis and neuronal function. We discuss its implication in α-Syn and Lewy body pathophysiological mechanisms underlying PD, focusing on the role of GCase and cholesterol. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society., This work was supported by grants from the Span-ish Ministries of Innovation, Science and Universities and Health, SocialServices and Equality and ISCIII, CIBERNED: PCIN2015-098,PID2019-111693RB-I00, CB06/05/0055, and PI2019/09-3; RamónAreces Foundation (172275); European Union’s Horizon 2020 researchand innovation program, AND-PD, grant agreement no. 848002 to R.M.;and NWO (grant no. BBOL-2007247202 to J.M.F.G.A.)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Role of Cholesterol in α-Synuclein and Lewy Body Pathology in GBA1 Parkinson's Disease

  • García-Sanz, Patricia
  • Aerts, Johannes
  • Moratalla, Rosario
Parkinson's disease (PD) is a progressive neurodegenerative disease where dopaminergic neurons in the substantia nigra are lost, resulting in a decrease in striatal dopamine and, consequently, motor control. Dopaminergic degeneration is associated with the appearance of Lewy bodies, which contain membrane structures and proteins, including α-synuclein (α-Syn), in surviving neurons. PD displays a multifactorial pathology and develops from interactions between multiple elements, such as age, environmental conditions, and genetics. Mutations in the GBA1 gene represent one of the major genetic risk factors for PD. This gene encodes an essential lysosomal enzyme called β-glucocerebrosidase (GCase), which is responsible for degrading the glycolipid glucocerebroside into glucose and ceramide. GCase can generate glucosylated cholesterol via transglucosylation and can also degrade the sterol glucoside. Although the molecular mechanisms that predispose an individual to neurodegeneration remain unknown, the role of cholesterol in PD pathology deserves consideration. Disturbed cellular cholesterol metabolism, as reflected by accumulation of lysosomal cholesterol in GBA1-associated PD cellular models, could contribute to changes in lipid rafts, which are necessary for synaptic localization and vesicle cycling and modulation of synaptic integrity. α-Syn has been implicated in the regulation of neuronal cholesterol, and cholesterol facilitates interactions between α-Syn oligomers. In this review, we integrate the results of previous studies and describe the cholesterol landscape in cellular homeostasis and neuronal function. We discuss its implication in α-Syn and Lewy body pathophysiological mechanisms underlying PD, focusing on the role of GCase and cholesterol. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society., This work was supported by grants from the Span-ish Ministries of Innovation, Science and Universities and Health, SocialServices and Equality and ISCIII, CIBERNED: PCIN2015-098,PID2019-111693RB-I00, CB06/05/0055, and PI2019/09-3; RamónAreces Foundation (172275); European Union’s Horizon 2020 researchand innovation program, AND-PD, grant agreement no. 848002 to R.M.;and NWO (grant no. BBOL-2007247202 to J.M.F.G.A.)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Restricting feeding to dark phase fails to entrain circadian activity and energy expenditure oscillations in Pitx3-mutant Aphakia mice

  • Fernández-Pérez, Antonio
  • Sanz-Magro, Adrián
  • Moratalla, Rosario
  • Vallejo, Mario
Metabolic homeostasis is under circadian regulation to adapt energy requirements to light-dark cycles. Feeding cycles are regulated by photic stimuli reaching the suprachiasmatic nucleus via retinohypothalamic axons and by nutritional information involving dopaminergic neurotransmission. Previously, we reported that Pitx3-mutant Aphakia mice with altered development of the retinohypothalamic tract and the dopaminergic neurons projecting to the striatum, are resistant to locomotor and metabolic entrainment by time-restricted feeding. In their Matters Arising article, Scarpa et al. (2022) challenge this conclusion using mice from the same strain but following a different experimental paradigm involving calorie restriction. Here, we address their concerns by extending the analyses of our previous data, by identifying important differences in the experimental design between both studies and by presenting additional results on the dopaminergic deficit in the brain of Aphakia mice. This Matters Arising Response article addresses the Matters Arising article by Scarpa et al. (2022), published concurrently in Cell Reports., Funded by the Spanish Ministry of Economy, Industry and Competitiveness (BFU2017-89336-R), by grant PID2020-117640RB-I00 funded by MICIN/AEI/10.13039/501100011033, and as appropriate, by “ERDF A way of making Europe,” by the “European Union” or by the “European Union NextGenerationEU/PRTR” (MICIN/CSIC/PTI+ NeuroAging), to M.V. and by grant PID2019-111693RB-100 funded by MICIN/AEI/10.13039/501100011033, by European Union's Horizon 2020 research and innovation program, AND-PD (grant agreement no. 84800), and by NextGenerationEU/PRTR (MICIN/CSIC/PTI+ NeuroAging) to R.M. CIBERDEM and CIBERNED are initiatives of the Instituto de Salud Carlos III.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Metabolic Diffusion in Neuropathologies: The Relevance of Brain-Liver Axis

  • Vegas-Suárez, S.
  • Simón, Jorge
  • Martínez-Chantar, María Luz
  • Moratalla, Rosario
Chronic liver diseases include a broad group of hepatic disorders from different etiologies and with varying degrees of progression and severity. Among them, non-alcoholic fatty (NAFLD) and alcoholic (ALD) liver diseases are the most frequent forms of expression, caused by either metabolic alterations or chronic alcohol consumption. The liver is the main regulator of energy homeostasis and metabolism of potentially toxic compounds in the organism, thus hepatic disorders often promote the release of harmful substances. In this context, there is an existing interconnection between liver and brain, with the well-named brain-liver axis, in which liver pathologies lead to the promotion of neurodegenerative disorders. Alzheimer’s (AD) and Parkinson’s (PD) diseases are the most relevant neurological disorders worldwide. The present work highlights the relevance of the liver-related promotion of these disorders. Liver-related hyperammonemia has been related to the promotion of perturbations in nervous systems, whereas the production of ketone bodies under certain conditions may protect from developing them. The capacity of the liver of amyloid-β (Aβ) clearance is reduced under liver pathologies, contributing to the development of AD. These perturbations are even aggravated by the pro-inflammatory state that often accompanies liver diseases, leading to the named neuroinflammation. The current nourishment habits, named as Western diet (WD) and alterations in the bile acid (BA) profile, whose homeostasis is controlled by the liver, have been also related to both AD and PD, whereas the supplementation with certain compounds, has been demonstrated to alleviate the pathologies., This work was supported by Grants from PID2019-111693RB-100 funded by MICIN /AEI/10.13039/501100011033, by European Union’s Horizon 2020 research and innovation program, AND-PD (Grant Agreement No.84800), and CSIC Interdisciplinary Thematic Platform (PTI+) NEURO-AGING+ and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) (CB06/05/00559 and PNSD 2016I033) to RM.PID2020-1171166RB-100 by MICIN to MM-C and of Health, Consumption and Social Welfare, Instituto de Salud Carlos III (ISCIII), Subprograma Retos Colaboración from ISCIII (RTC2019-007125) to JS and MM-C; Fundación Científica AECC Rare Tumor Calls 2017 (to MM-C), La Caixa Foundation Program (HR17-00601 to MM-C); Proyectos Investigación en Salud (DTS20/00138 to JS and MM-C); Departamento de Industria del Gobierno Vasco to MM-C; CIBEREHD (EHD21TRF01) to MM-C. SV-S has a postdoctoral grant Margarita Salas (MARSA21/84) from Spanish Ministries of Universities and European Union-Next GenerationEU through the UPV/EHU and CSIC.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Metabolic Diffusion in Neuropathologies: The Relevance of Brain-Liver Axis

  • Vegas-Suárez, S.
  • Simón, Jorge
  • Martínez-Chantar, María Luz
  • Moratalla, Rosario
Chronic liver diseases include a broad group of hepatic disorders from different etiologies and with varying degrees of progression and severity. Among them, non-alcoholic fatty (NAFLD) and alcoholic (ALD) liver diseases are the most frequent forms of expression, caused by either metabolic alterations or chronic alcohol consumption. The liver is the main regulator of energy homeostasis and metabolism of potentially toxic compounds in the organism, thus hepatic disorders often promote the release of harmful substances. In this context, there is an existing interconnection between liver and brain, with the well-named brain-liver axis, in which liver pathologies lead to the promotion of neurodegenerative disorders. Alzheimer’s (AD) and Parkinson’s (PD) diseases are the most relevant neurological disorders worldwide. The present work highlights the relevance of the liver-related promotion of these disorders. Liver-related hyperammonemia has been related to the promotion of perturbations in nervous systems, whereas the production of ketone bodies under certain conditions may protect from developing them. The capacity of the liver of amyloid-β (Aβ) clearance is reduced under liver pathologies, contributing to the development of AD. These perturbations are even aggravated by the pro-inflammatory state that often accompanies liver diseases, leading to the named neuroinflammation. The current nourishment habits, named as Western diet (WD) and alterations in the bile acid (BA) profile, whose homeostasis is controlled by the liver, have been also related to both AD and PD, whereas the supplementation with certain compounds, has been demonstrated to alleviate the pathologies., This work was supported by Grants from PID2019-111693RB-100 funded by MICIN /AEI/10.13039/501100011033, by European Union’s Horizon 2020 research and innovation program, AND-PD (Grant Agreement No.84800), and CSIC Interdisciplinary Thematic Platform (PTI+) NEURO-AGING+ and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) (CB06/05/00559 and PNSD 2016I033) to RM.PID2020-1171166RB-100 by MICIN to MM-C and of Health, Consumption and Social Welfare, Instituto de Salud Carlos III (ISCIII), Subprograma Retos Colaboración from ISCIII (RTC2019-007125) to JS and MM-C; Fundación Científica AECC Rare Tumor Calls 2017 (to MM-C), La Caixa Foundation Program (HR17-00601 to MM-C); Proyectos Investigación en Salud (DTS20/00138 to JS and MM-C); Departamento de Industria del Gobierno Vasco to MM-C; CIBEREHD (EHD21TRF01) to MM-C. SV-S has a postdoctoral grant Margarita Salas (MARSA21/84) from Spanish Ministries of Universities and European Union-Next GenerationEU through the UPV/EHU and CSIC.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Motor cortico-nigral and cortico-entopeduncular information transmission and its modulation by buspirone in control and after dopaminergic denervation

  • Vegas-Suárez, S.
  • Morera-Herreras, T.
  • Requejo, Catalina
  • Lafuente, J.V.
  • Moratalla, Rosario
  • Miguélez, C.
  • Ugedo, Luisa
Cortical information is transferred to the substantia nigra pars reticulata (SNr) and the entopeduncular nucleus (EP), the output structures of the basal ganglia (BG), through three different pathways: the hyperdirect trans-subthalamic and the direct and indirect trans-striatal pathways. The nigrostriatal dopamine (DA) and the activation of 5-HT receptors, distributed all along the BG, may modulate cortical information transmission. We aimed to investigate the effect of buspirone (5-HT receptor partial agonist) and WAY-100635 (5-HT receptor antagonist) on cortico-nigral and cortico-entopeduncular transmission in normal and DA loss conditions. Herein, simultaneous electrical stimulation of the motor cortex and single-unit extracellular recordings of SNr or EP neurons were conducted in urethane-anesthetized sham and 6-hydroxydopamine (6-OHDA)-lesioned rats before and after drug administrations. Motor cortex stimulation evoked monophasic, biphasic, or triphasic responses, combination of an early excitation, an inhibition, and a late excitation in both the SNr and EP, while an altered pattern of evoked response was observed in the SNr after 6-OHDA lesion. Systemic buspirone potentiated the direct cortico-SNr and cortico-EP transmission in sham animals since increased duration of the inhibitory response was observed. In DA denervated animals, buspirone administration enhanced early excitation amplitude in the cortico-SNr transmission. In both cases, the observed effects were mediated via a 5-HT-dependent mechanism as WAY-100635 administration blocked buspirone’s effect. These findings suggest that in control condition, buspirone potentiates direct pathway transmission and DA loss modulates responses related to the hyperdirect pathway. Overall, the results may contribute to understanding the role of 5-HT receptors and DA in motor cortico-BG circuitry functionality., This work was financially supported by the Spanish Ministry of Economy and Competitiveness (SAF 2016‐77758-R AEI/ FEDER, UE), the Basque Government (T747-13 and PUE21- 03), and University of the Basque Country, UPV/EHU (GIU19/ 092 and COLAB20/07) to LU and CM. This research was conducted in the scope of the Transborder Joint Laboratory (LTC) “non-motor Comorbidities in Parkinson’s Disease (CoMorPD)” and PID2 021-126434OB-I00 grant supported by the Spanish Ministry of Science and Innovation to CM. This work was also supported by grants from PID 2019-111693RB-100 was funded by MICIN/AEI/10.13039/501100011033, by the European Union’s Horizon 2020 research and innovation program, AND-PD (grant agreement no. 84800), Next Generation EU/PRTR (MICIN/CSIC/PTI+ NeuroAging) to RM, and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas [CIBERNED] (CB06/05/00559 and PNSD2016I033) to RM and SV-S. SV-S received a predoctoral fellowship from the UPV/EHU and a postdoctoral Margarita Salas fellowship (MARSA21/84) from Spanish Ministries of Universities and European Union-Next Generation EU through the UPV/EHU and CSIC. SV-S has a JdC-f postdoctoral fellowship funded by Spanish State Research Agency and European Union-Next Generation EU.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

D2 dopamine receptors and the striatopallidal pathway modulate L-DOPA-induced dyskinesia in the mouse

  • Sáez, María
  • Keifman, Ettel
  • Alberquilla, Samuel
  • Coll, Camila
  • Reig, Ramón
  • Murer, Mario Gustavo
  • Moratalla, Rosario
L-DOPA-induced dyskinesia (LID) remains a major complication of Parkinson's disease management for which better therapies are necessary. The contribution of the striatonigral direct pathway to LID is widely acknowledged but whether the striatopallidal pathway is involved remains debated. Selective optogenetic stimulation of striatonigral axon terminals induces dyskinesia in mice rendered hemiparkinsonian with the toxin 6-hydroxydopamine (6-OHDA). Here we show that optogenetically-induced dyskinesia is increased by the D2-type dopamine receptor agonist quinpirole. Although the quinpirole effect may be mediated by D2 receptor stimulation in striatopallidal neurons, alternative mechanisms may be responsible as well. To selectively modulate the striatopallidal pathway, we selectively expressed channelrhodopsin-2 (ChR2) in D2 receptor expressing neurons by crossing D2-Cre and ChR2-flox mice. The animals were rendered hemiparkinsonian and implanted with an optic fiber at the ipsilateral external globus pallidus (GPe). Stimulation of ChR2 at striatopallidal axon terminals reduced LID and also general motility during the off L-DOPA state, without modifying the pro-motor effect of low doses of L-DOPA producing mild or no dyskinesia. Overall, the present study shows that D2-type dopamine receptors and the striatopallidal pathway modulate dyskinesia and suggest that targeting striatopallidal axon terminals at the GPe may have therapeutic potential in the management of LID., This work was supported by Fondo para la Investigación Científica y Tecnológica (FONCYT), Proyecto de Investigación Científica y Tecnológica Grants PICT 2018-2738 and PICT 2020-325; by Universidad de Buenos Aires UBACYT grant 2018-305A. M.S. was supported by Ministerio de Ciencia e Innovación “Ayudas Juan de la Cierva-formación” FJC2021-047618-I grant. Work in the lab of R.M. was supported by grant number PID2019- 111693RB-100 from MICIN/AEI/10.13039/501100011033 and by European Union's Horizon 2020 research and innovation program, AND-PD (grant agreement no. 84800), and by NextGenerationEU/PRTR (MICIN/CSIC/PTI+ NeuroAging). We thank Jésica Unger, Lucía Garbini, Verónica Risso and Graciela Ortega for excellent technical assistance., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Dopaminergic Input Regulates the Sensitivity of Indirect Pathway Striatal Spiny Neurons to Brain-Derived Neurotrophic Factor

  • Ayon-Olivas, Maurilyn
  • Wolf, Daniel
  • Andreska, Thomas
  • Granado, Noelia
  • Lüningschrör, Patrick
  • Ip, Chi Wang
  • Moratalla, Rosario
  • Sendtner, Michael
Motor dysfunction in Parkinson’s disease (PD) is closely linked to the dopaminergic depletion of striatal neurons and altered synaptic plasticity at corticostriatal synapses. Dopamine receptor D1 (DRD1) stimulation is a crucial step in the formation of long-term potentiation (LTP), whereas dopamine receptor D2 (DRD2) stimulation is needed for the formation of long-term depression (LTD) in striatal spiny projection neurons (SPNs). Tropomyosin receptor kinase B (TrkB) and its ligand brain-derived neurotrophic factor (BDNF) are centrally involved in plasticity regulation at the corticostriatal synapses. DRD1 activation enhances TrkB’s sensitivity for BDNF in direct pathway spiny projection neurons (dSPNs). In this study, we showed that the activation of DRD2 in cultured striatal indirect pathway spiny projection neurons (iSPNs) and cholinergic interneurons causes the retraction of TrkB from the plasma membrane. This provides an explanation for the opposing synaptic plasticity changes observed upon DRD1 or DRD2 stimulation. In addition, TrkB was found within intracellular structures in dSPNs and iSPNs from Pitx3−/− mice, a genetic model of PD with early onset dopaminergic depletion in the dorsolateral striatum (DLS). This dysregulated BDNF/TrkB signaling might contribute to the pathophysiology of direct and indirect pathway striatal projection neurons in PD., This research was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) project 424778381 (TRR 295, A05). Work in the lab of R.M. was supported by grant PID2019-111693RB-I00 from MICIN/AEI10.13039/501100011033, the European Union’s Horizon 2020 research and innovation program, AND-PD (grant 84800), NextGenerationEU/PRTR (MICIN/CSIC/PTI+ NeuroAging), and CIBERNED, Instituto de Salud Carlos III., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Whole-brain 3D imaging of dopaminergic systems in cleared Pitx3-deficient aphakia mouse brains reveals region-specific impairments

  • Juárez-Escoto, Elena
  • Kral, Jenny
  • Jurado, Sandra
  • Moratalla, Rosario
Resumen del póster presentado al 11th IBRO World Congress of Neuroscience, celebrado en Granada (España) del 9 al 13 de septiembre de 2023., Pitx3 is a homeobox transcription factor critical for the development and maintenance of midbrain dopaminergic (DA) neurons, i.e.: substantia nigra (SN) neurons (A9 group), ventral tegmental area (VTA) neurons (A10 group), and retrorubral field neurons (A8 group). Nevertheless, different midbrain DA neuron subsets display distinct Pitx3 dependence and, in fact, Pitx3 expression has been found to correlate with the neuronal vulnerabilities reported in midbrains from Parkinson’s disease (PD) patients. The aphakia (Ak) mouse is characterized by a congenital severe knockdown of the Pitx3 gene, and these animals show a dramatic loss of DA neurons in the SN and, to a lesser extent, in the VTA. Ak mice exhibit motor phenotypes, but also striatum-dependent cognitive impairments, and olfactory and gastrointestinal dysfunctions, mimicking prodromal and early stages of PD; however, it remains unclear how Pitx3 deficiency drives this heterogeneous symptomatology. In order to dissect the changes occurring in the DA systems from the Ak mouse brains, we performed immunolabeling-enabled three-dimensional imaging of solvent cleared organs, or iDISCO+ clearing method. We resolved catecholaminergic nuclei at the single-cell resolution to determine other brain regions and systems affected upon Pitx3 deficiency and DA loss. iDISCO+ revealed region-specific impairments in Ak mouse brains that could explain the occurrence of pre-motor symptoms in this model. Our results contribute to the understanding of the Ak mouse as a PD model and to determine the neuronal vulnerabilities underlying the main PD co-morbidities., Funded by Spanish Ministries of Science and Innovation (PID2019-111693RB-I00 and PID2019-108851RB-C21) and UE (H2020-SC1-BHC-2018-2020, grant agreement n° 848002 and by NextGeneration EU/PRTR (MICIN/CSIC/PTI+ NeuroAging)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

APOE E4 allele, along with G206D-PSEN1 mutation, alters mitochondrial networks and their degradation in Alzheimer's disease

  • Costa Laparra, Irene
  • Juárez-Escoto, Elena
  • Vicario-Abejón, Carlos
  • Moratalla, Rosario
  • García-Sanz, Patricia
Introduction Alzheimer's disease remains the most common neurodegenerative disorder, depicted mainly by memory loss and the presence in the brain of senile plaques and neurofibrillary tangles. This disease is related to several cellular alterations like the loss of synapses, neuronal death, disruption of lipid homeostasis, mitochondrial fragmentation, or raised oxidative stress. Notably, changes in the autophagic pathway have turned out to be a key factor in the early development of the disease. The aim of this research is to determine the impact of the APOE allele E4 and G206D-PSEN1 on the underlying mechanisms of Alzheimer's disease. Methods Fibroblasts from Alzheimer's patients with APOE 3/4 + G206D-PSEN1 mutation and homozygous APOE E4 were used to study the effects of APOE polymorphism and PSEN1 mutation on the autophagy pathway, mitochondrial network fragmentation, superoxide anion levels, lysosome clustering, and p62/SQSTM1 levels. Results We observed that the APOE allele E4 in homozygosis induces mitochondrial network fragmentation that correlates with an increased colocalization with p62/SQSTM1, probably due to an inefficient autophagy. Moreover, G206D-PSEN1 mutation causes an impairment of the integrity of mitochondrial networks, triggering high superoxide anion levels and thus making APOE 3/4 + PSEN1 fibroblasts more vulnerable to cell death induced by oxidative stress. Of note, PSEN1 mutation induces accumulation and clustering of lysosomes that, along with an increase of global p62/SQSTM1, could compromise lysosomal function and, ultimately, its degradation. Conclusion The findings suggest that all these modifications could eventually contribute to the neuronal degeneration that underlies the pathogenesis of Alzheimer's disease. Further research in this area may help to develop targeted therapies for the treatment of Alzheimer's disease., This work was supported by grants from the Spanish Ministries of Science and Innovation (SAF2016-78207 and PID2019-111693RB-I00), from the European Union’s Horizon 2020 Research and Innovation Program (AND-PD, grant agreement n◦ 848,002), and by Next Generation EU/PRTR (MICIN/CSIC/PTI+ NeuroAging), Health, Social Services and Equality (PI2019/09-3) and CIBERNED, Instituto de Salud Carlos III (CB06/05/0055, CB06/05/0065, PI2013/01-6, PI2015-2/02-5, and PI2015-2/02-4)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

DRD1 signaling modulates TrkB turnover and BDNF sensitivity in direct pathway striatal medium spiny neurons

  • Moratalla, Rosario
  • Lüningschrör, Patrick
  • Wolf, D.
  • McFleder, R.L.
  • Ayon-Olivas, Maurilyn
  • Rattka, M.
  • Drechsler, C.
  • Perschin, V.
  • Blum, Robert
  • Aufmkolk, S
  • Granado, Noelia
  • Moratalla, Rosario
  • Sauer, Markus
  • Monoranu, C.
  • Volkmann, J.
  • Ip, Chi Wang
  • Stigloher, Christian
  • Sendtner, Michael
Disturbed motor control is a hallmark of Parkinson's disease (PD). Cortico-striatal synapses play a central role in motor learning and adaption, and brain-derived neurotrophic factor (BDNF) from cortico-striatal afferents modulates their plasticity via TrkB in striatal medium spiny projection neurons (SPNs). We studied the role of dopamine in modulating the sensitivity of direct pathway SPNs (dSPNs) to BDNF in cultures of fluorescence-activated cell sorting (FACS)-enriched D1-expressing SPNs and 6-hydroxydopamine (6-OHDA)-treated rats. DRD1 activation causes enhanced TrkB translocation to the cell surface and increased sensitivity for BDNF. In contrast, dopamine depletion in cultured dSPN neurons, 6-OHDA-treated rats, and postmortem brain of patients with PD reduces BDNF responsiveness and causes formation of intracellular TrkB clusters. These clusters associate with sortilin related VPS10 domain containing receptor 2 (SORCS-2) in multivesicular-like structures, which apparently protects them from lysosomal degradation. Thus, impaired TrkB processing might contribute to disturbed motor function in PD., This work was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) project 424778381 (TRR295, A05, A06, and A01), project SE697/7-1, and project 218894895 (INST93/761-1FUGG). R.L.M.was supported by the Alexander von Humboldt-Stiftung. V.P. and C.S.were supported by GRK2581 (P6) SPHINGOINF of the DFG.Work in the lab of R.M. was supported by grant PID2019-111693RB-100 from MICIN/AEI/10.13039/501100011033, the European Union’s Horizon 2020 research and innovation program, AND-PD (grant 84800),Next Generation EU/PRTR (MICIN/CSIC/PTI+NeuroAging), and CIBERNED, Instituto de Salud Carlos III. The graphical abstract was created with BioRender.com. We thank Drs.James Surmeier, Moses Chao, and Esther Asan for critical comments and suggestions.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Novel Pharmacotherapies for L-DOPA-Induced Dyskinesia

  • Tizabi, Yousef
  • Getachew, Bruk
  • Copeland, Robert L.
  • Moratalla, Rosario
  • Patricio, Felipe
  • Limón, Ilhuicamina Daniel
  • Del-Bel, Elaine
  • Aschner, Michael
Dyskinesia or abnormal involuntary movement is an unfortunate consequence of long-term therapy with L-DOPA, a gold standard for the treatment of Parkinson’s disease (PD). L-DOPA-induced dyskinesia (LID) is affected by age of onset, duration and severity of PD, L-DOPA dose, as well as gender. The main treatment modality is reduction of L-DOPA dose. Although administration of apomorphine, amantadine, and clozapine may be helpful, more effective pharmacotherapies are urgently needed. Recent advances in our understanding of the pathophysiology of LID have led to suggestions of novel interventions. In this chapter, three classes of drugs, nicotinic receptor agonists, glutamatergic N-methyl-D-aspartate (NMDA) receptor antagonists, and cannabinoid receptor agonists, where their effectiveness in preclinical studies has been established, will be discussed in detail., Supported in part by the Howard University College of Medicine Bridge Funds and Pilot Study Awards Program (BFPSAP) 2020–2021 (YT, RLC); Spanish Ministry of Science and Innovation (PID2019-111693RBI00) and European Union’s Horizon 2020 research and innovation program, AND-PD (grant agreement no. 848002) (RM); VIEP-BUAP 2020-2021(IDL); São Paulo State Foundation for the Support of Research (FAPESP, Brazil; Grants 2014/25029-4 and 2017/24304-0), CAPES-COFECUB Grant #848/15) (EDB); and NIH/NIEHS R01ES10563 (MA)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Attenuated neurotoxicity after repeated methamphetamine binges linked to dopamine transporter (DAT) decline

  • Granado, Noelia
  • Mendieta, L.
  • Tizabi, Yousef
  • Murer, Mario Gustavo
  • Moratalla, Rosario
Methamphetamine (METH) abuse increases worldwide. In addition to its acute life-threatening effects, METH is toxic for dopaminergic neurons, increasing the risk of developing Parkinson's disease. The impact of repeated METH binge consumption on dopaminergic and neurotoxicity markers remains unclear. We exposed mice to a repeated “binge-like” METH regime, consisting of three doses over a 6 h interval, repeated three times with 14-day intervals. After the first binge, spontaneous motor activity decreased markedly but remained normal after subsequent binges. Following the first binge, we observed a 25 % loss of nigral dopaminergic cell bodies and significant axon terminal damage as assessed through striatal silver staining, with minimal further degeneration after additional binges. Dopaminergic markers were substantially depleted after the first and second binges, despite partial recovery between binges, dropping to below 20 % of control levels. By one day after the third binge, tyrosine hydroxylase (TH) and vesicular monoamine transporter 2 (VMAT2) stabilized at 50–60 % of control levels, but the dopamine transporter (DAT) remained at only 25 %, showing less recovery. These changes were accompanied by an evolving neuroinflammation pattern, with a transient microglial surge after the first binge and persistent astroglial and temperature responses. Overall, our findings indicate partial recovery of dopaminergic markers and the development of tolerance to METH neurotoxicity. The robust reduction of DAT after the first binge may contribute to this tolerance to subsequence binges by limiting METH entry into neurons thereby mitigating its neurotoxic effects., This work was supported by Grants PID 2019-111693RB-100 and PID 2022-148131OB-100, funded by MICIN /AEI/10.13039/ 501100011033, and by European Union’s Horizon 2020 research and innovation program, AND-PD (Grant Agreement No. 84800), CSIC Interdisciplinary Thematic Platform (PTI+) NEURO-AGING+ and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, and PIDAE from Universidad de Buenos Aires.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Astrocytes Mediate Psychostimulant-Induced Alterations of Spike-Timing Dependent Synaptic Plasticity

  • Alberquilla, Samuel
  • Nanclares, Carmen
  • Expósito, Sara
  • Gall, G,
  • Kofuji, Paulo
  • Araque, Alfonso
  • Martín, Eduardo D.
  • Moratalla, Rosario
At cellular and circuit levels, drug addiction is considered a dysregulation of synaptic plasticity. In addition, dysfunction of the glutamate transporter 1 (GLT-1) in the nucleus accumbens (NAc) has also been proposed as a mechanism underlying drug addiction. However, the cellular and synaptic impact of GLT-1 alterations in the NAc remain unclear. Here we show in the NAc that 10¿days withdraw after 5¿days treatment with cocaine or amphetamine decreases GLT-1 expression in astrocytes, which results in the prolongation of the excitatory postsynaptic potential (EPSP) decay kinetics in D1 receptor-containing medium spiny neurons (D1R-MSNs). Using the spike timing dependent plasticity (STDP) paradigm, we found that enlargement of EPSP duration results in switching the LTP elicited in control animals to LTD in psychostimulant-treated mice. In contrast to D1-MSNs, D2-MSNs did not display changes in EPSP kinetics and synaptic plasticity. Notably, the psychostimulant-induced synaptic transmission and synaptic plasticity effects were absent in IP3R2¿/¿ mice, which lack astrocyte calcium signal, but were mimicked by the selective astrocytes stimulation with DREADDs. Finally, ceftriaxone, which upregulates GLT-1, restored normal GLT-1 function, EPSP kinetics, and synaptic plasticity in psychostimulant-treated mice. Therefore, we propose that cocaine and amphetamine increase dopaminergic levels in the NAc, which stimulates astrocytes and downregulates the GLT-1. The decreased GLT-1 function prolonged the EPSP kinetics, leading to the modulation of the STDP, transforming the LTP observed in control animals into LTD in psychostimulant-treated mice. Present work reveals a novel mechanism underlying the synaptic plasticity changes induced by these drugs of abuse., This work was supported by grants PID 2019-111693RB100 and PID2022 143181OB-100 to R.M. and PID2020-116327GB-I00 to E.D.M. funded by MCIN/AEI/ 10.13039/501100011033, Spanish Ministerio de Ciencia, Innovacion y Universidades. Grants NIH-NIMH R01MH119355 and NIH-NIDA R01DA048822 to A.A. funded by National Institutes of Health and grant W911NF2110328 to A.A. funded by Department of Defense.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Two factor model of L-DOPA-induced dyskinesia: bridging early clinical findings with modern mechanistic understanding.

  • Moratalla, Rosario
  • Murer, Mario Gustavo
l-DOPA-induced dyskinesia (LID) remains a major complication of dopaminergic therapy in Parkinson's disease (PD), and serves as a model for studying maladaptive plasticity induced by dopaminergic overstimulation, with relevance to other disorders such as addiction. Chronic striatal dopamine depletion is crucial for LID development, inducing pruning of corticostriatal synapses—particularly on direct pathway medium spiny neurons (dMSNs)—and thereby distorting striatal input-output mapping. Superimposed on this structural remodeling, repeated pulsatile l-DOPA treatment leads to sensitization of dMSNs, resulting in heightened dopaminergic and glutamatergic responsiveness, impaired synaptic depotentiation, and recruitment of hyperactive dMSN ensembles during dyskinesia. Concurrently, indirect pathway MSNs (iMSNs) undergo dynamic adaptations in excitability and ensemble activity that modulate the threshold for LID expression, possibly through disinhibition of dMSN output. Recent optogenetic studies in parkinsonian mice support a model in which dopaminergic denervation alone sculpts a dMSN network capable of producing dyskinesia upon activation even in animals never previously exposed to dopamine receptor stimulation. Intermittent l-DOPA administration further sensitizes this network without qualitatively altering the abnormal movements. In parallel, iMSN optogenetic inhibition produces therapeutic effects, while their stimulation reduces established LID, indicating a modulatory role for the indirect pathway. These findings support a two-factor model of LID in which (1) striatal denervation distorts corticostriatal input-output relationships, and (2) plastic changes in dMSNs and iMSNs lower the threshold for dyskinetic output in response to dopaminergic stimulation. In early PD, the therapeutic effects of l-DOPA are likely mediated by balanced D2 receptor stimulation on iMSNs and D1 receptor stimulation in dMSNs, providing symptom relief without provoking dyskinesia. However, disease progression and chronic l-DOPA therapy appear to partially reverse denervation-induced changes in iMSNs, including normalization of D2 receptor expression, restoration of intrinsic excitability, and partial recovery of dendritic spine density, which could contribute to a gradual desensitization of D2/iMSN influence over time, leading to an increased reliance on dMSN-mediated mechanisms for both therapeutic and dyskinetic effects. This hypothesis offers a mechanistic explanation for the temporal dissociation between the therapeutic and dyskinetic effects of l-DOPA in early disease, and their progressive narrowing of the therapeutic window as disease and treatment duration advance., We thank Cecilia Tubert (IFIBIO Houssay, Buenos Aires, Argentina) for her assistance with the figures. This work was supported by grants from the Universidad de Buenos Aires, PIDAE 2024-7, and FONCYT, PICT 2020 325 (MGM), and PID 2022-148131OB-100, funded by MICIN/AEI/10.13039/501100011033, and by European Union’s Horizon 2020 research and innovation program, AND-PD (Grant Agreement No. 84800), MJFF-022990, CSIC Interdisciplinary Thematic Platform (PTI+) NEURO-AGING+ and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III (RM).